La sensibilisation aux risques du cancer du mélanome de la peau auprès des patients MG traités par azathioprine.

Rubrique ouverte à tous en lecture seule.
POUR ACCEDER AUX NOMBREUX AUTRES FORUMS IL EST NECESSAIRE DE S'INSCRIRE (fonction M'enregistrer en haut à droite de l'écran).
Répondre
Avatar du membre

Auteur du sujet
Pboulanger
Administrateur
Administrateur
Messages : 4716
Enregistré le : 02 févr. 2010 18:41
Localisation : La Chapelle en Serval F-60520
    Windows 8.1 Firefox
Genre :
Zodiaque : Lion
Âge : 61
Contact :
France

La sensibilisation aux risques du cancer du mélanome de la peau auprès des patients MG traités par azathioprine.

Message par Pboulanger » 21 nov. 2015 03:55

:hi:

Lu sur publimed http://www.ncbi.nlm.nih.gov/pubmed/26516615 cette étude intitulée
La sensibilisation aux risques du cancer du mélanome de la peau auprès des patients myasthéniques traités par azathioprine
Traduction disponible directement en cliquant en bas à droite de ce message sur notre forum
Image
Brain Behav. 2015 Sep 15;5(10):e00396. doi: 10.1002/brb3.396. eCollection 2015.
Nonmelanoma skin cancer risk awareness in azathioprine-treated myasthenia gravis patients.
McGurgan IJ1, McGuigan C1.
Author information


Abstract
  • OBJECTIVES:

    Increased rates of NMSC (nonmelanoma skin cancer) have recently been reported in people with MG (myasthenia gravis) receiving azathioprine treatment. Guidelines on azathioprine for patients with dermatological and gastrointestinal disorders stress the importance of NMSC risk awareness and prevention. The aim of this study is to assess whether MG patients are being informed of this risk.
  • METHODS:

    Clinical records of patients with MG attending a university hospital neurology clinic were reviewed. Data on patient demographics, clinical presentation, diagnostic tests, azathioprine treatment, development of NMSC, and counseling regarding NMSC risk were recorded.
  • RESULTS:

    Sixty-nine MG cases were identified, median age 58 years (range 20-90). Forty-two (60.9%) had received azathioprine at some point with a mean cumulative dose of 235.5 g (range 9.1-972.8 g). Skin cancer risk and prevention advice provision was documented in 3 (7.1%) azathioprine-treated patients. Five patients developed histologically confirmed NMSC of whom all were treated with azathioprine (incidence rate of 24.9 per 1000, 16 times higher than expected). Documented advice on other safety issues such as regular blood test monitoring was found in 33 (78.8%) azathioprine-treated cases.
  • CONCLUSIONS:

    Preventative measures such as daily sunscreen use have been shown to reduce the incidence of NMSC in the general population. The results of this study demonstrate a very low rate of advice provision about NMSC risk in azathioprine-treated MG patients and the need for increased awareness among treating neurologists and patients
.
Amicalement,
Image

Répondre

Retourner vers « Informations »